Management of Patients with Penicillin and Cephalosporin Allergies

Introduction to Allergy Management

• The Dutch Working Party on Antibiotic Policy (SWAB) provides guidance on cross-reactivity, stating that patients with immediate-type penicillin allergy can safely receive carbapenems and monobactams (except aztreonam with ceftazidime allergy), and that cephalosporins with similar side chains to the penicillin that caused the reaction should be avoided 1
• True cross-reactivity between penicillin and cephalosporins is less common than previously thought, especially with newer generation cephalosporins, according to the available evidence 2

Patient Assessment and Risk Factors

• High-risk patients who should definitely be admitted include those with a history of anaphylaxis to beta-lactams, significant comorbidities, signs of severe infection or sepsis, or hemodynamic instability 1
• The American College of Physicians recommends assessing the patient's risk category before selecting antibiotics, including factors such as prolonged neutropenia, low absolute neutrophil count (ANC), significant comorbidities, hemodynamic instability, and requirement for hospitalization for IV therapy 3

Antibiotic Therapy

• Vancomycin is effective against most gram-positive organisms, including MRSA, and is indicated for penicillin-allergic patients, but its use should be guided by clinical judgment and susceptibility patterns 1
• The choice of antibiotic therapy should be based on the suspected pathogens involved and the specific infection site, with consideration of adding agents for gram-negative or anaerobic coverage 2
• For patients with neutropenic fever and a history of immediate-type penicillin hypersensitivity reaction, a combination regimen of aztreonam plus vancomycin is strongly recommended as the initial empiric therapy, according to the Infectious Diseases Society of America 3
• Most penicillin-allergic patients can tolerate cephalosporins, and a recommended regimen is cefepime or carbapenem monotherapy, as suggested by the Infectious Diseases Society of America 3
• An alternative regimen of ciprofloxacin plus clindamycin may be considered, according to the Infectious Diseases Society of America 3

Documentation and Treatment Duration

• It is essential to document the specific nature of previous allergic reactions, as the type of reaction (immediate vs. delayed) significantly impacts antibiotic selection 2
• For admitted patients, antibiotic therapy should be continued until clinical improvement is observed, culture results guide targeted therapy, or the full course of appropriate antibiotics is completed 1
• For documented infections, antibiotics should be continued for at least the duration of neutropenia (until ANC >500 cells/mm³), according to the Infectious Diseases Society of America 3
• For unexplained fever, the initial regimen should be continued until clear signs of marrow recovery, as recommended by the Infectious Diseases Society of America 3
• Vancomycin should be added to aztreonam in high-risk patients because gram-positive bacteria account for approximately 60-70% of documented infections in neutropenic patients, according to the Infectious Diseases Society of America 4
• Vancomycin provides coverage for MRSA and other resistant gram-positive organisms, but should be discontinued after 2-3 days if no gram-positive infection is identified, as recommended by the Infectious Diseases Society of America 3
• Empiric antibiotics should be administered promptly to all neutropenic patients at the onset of fever, according to the Infectious Diseases Society of America 3
• Inadequate gram-negative coverage can lead to high mortality in neutropenic patients, and ensuring robust coverage against Pseudomonas aeruginosa is essential, as recommended by the Infectious Diseases Society of America 3
• Patients on fluoroquinolone prophylaxis should not receive fluoroquinolone-based empiric therapy, as recommended by the Infectious Diseases Society of America 3
• For truly low-risk patients, oral ciprofloxacin plus clindamycin may be considered, according to the Infectious Diseases Society of America 3